This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $427,625.00 to The Washington University in St. Louis to develop a novel in vitro model for studying amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research project will employ direct neuronal conversion to generate induced motor neurons and cortical...
This $1,157,896 Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), will fund research at Brown University focused on elucidating the mechanistic basis of transketolase-mediated suppression of neurodegeneration in amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD). The grantee will study multiple models of ALS/FTD using Drosophila genetics and analyze molecular readouts such as redox state, autophagy,...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $697,907 to Thomas Jefferson University to investigate the role of the C-JUN/transposable element (TE)/cGAS/STING pathway in the pathogenesis of C9ORF72-associated amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). The key products and services...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $120,504 to Carnegie Mellon University to develop peptide nucleic acid (PNA) oligomers for targeted disruption of biomolecular condensates in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The key objectives are to: (a) fluorescently label RNAs suspected of participating in biomolecular condensates, and (b) disrupt...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,001,864 to Harvard University to investigate the subcellular mechanisms underlying the selective vulnerability of specific neuron subtypes in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The researchers will quantitatively study the localization of RNA, proteins, and translational regulation in the synapses and soma of vulnerable corticospinal neurons (CSN) and...
The National Institute on Aging (NIA) awarded a $630,496 Project Grant under the Aging Research program (CFDA 93.866) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The 5-year grant, awarded on June 1, 2025, supports research to investigate the underlying mechanisms of proteostasis dysfunction and neuroinflammation in frontotemporal dementia (FTD) caused by granulin (GRN) deficiency. The research aims to better define alterations in...
This $224,140 Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) supports research to elucidate the mechanisms of circuit dysfunction in frontotemporal dementia (FTD) caused by the C9ORF72 gene mutation. The research aims to monitor the progression of neuronal activity and its relationship to neuronal loss, as well as determine whether neuronal hyperactivity can drive the progression of FTD pathology and behavioral deficits. The award recipient, The General...
This $432,802 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research focused on identifying gene expression changes associated with the C9ORF72 mutation in frontotemporal dementia (FTD). The primary awardee, Pennsylvania State University (doing business as Penn State Milton S. Hershey Medical Center), will cross-validate...
This federal Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to improve understanding of frontotemporal lobar degeneration (FTLD), a group of neurodegenerative disorders. The total award amount is $1,076,760.00 and the performance period runs from September 30, 2024 to August 31, 2029. The key objectives of this grant are to: 1) Generate a humanized FTLD-TDP mouse model by transplanting patient-derived microglia into mice...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting the development and optimization of a new animal model for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The $374,349 award to the University of North Carolina at Chapel Hill aims to demonstrate the progressive ALS/FTD-like phenotype in aged cohorts of...